Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.52 |
| ▸ | FURIN | P09958 | 1/20 | 0.49 |
| ▸ | UBE2T | Q9NPD8 | 2/20 | 0.45 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23906967 | 0.98 | NNMT (0.66) | NNMTMKNK1MKNK2PRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL31152512 | 0.98 | NNMT (0.66) | NNMTMKNK1MKNK2PRSS1PRSS2 | |
| SCHEMBL513126 | 0.81 | NNMT (0.68) | NNMTMKNK1MKNK2SIRT6 | |
| SCHEMBL29975550 | 0.81 | NNMT (1.00) | NNMTMKNK1MKNK2OPRM1OPRD1 | |
| SCHEMBL71905 | 0.81 | NNMT (1.00) | NNMTMKNK1MKNK2OPRM1OPRD1 | |
| SCHEMBL17984748 | 0.80 | FURIN (0.46) | NNMTPRSS1PRSS2PRSS3FURIN | |
| Hydrochloric Acid SCHEMBL6234386 | 0.79 | NNMT (0.96) | NNMTMKNK1MKNK2OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL5013391 | 0.79 | NNMT (0.96) | NNMTMKNK1MKNK2OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL2079102 | 0.79 | NNMT (0.66) | NNMTMKNK1MKNK2SIRT6 | |
| SCHEMBL25404032 | 0.79 | FURIN (0.48) | NNMTPRSS1PRSS2PRSS3FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023135057-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-07-20 | — | — | WO | disclosed |
| US-9174980-B2 | Heterocyclic compounds as inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9174980-B2 | Heterocyclic compounds as inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| WO-2013116182-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-08 | — | — | WO | disclosed |
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| EP-1874777-B1 | 1H-PYRIMIDO[4,5-B]INDOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2011-06-08 | — | — | EP | disclosed |
| US-20090215741-A1 | 1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and Therapeutic Use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-7547706-B2 | 1H-pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| US-20080125410-A1 | 7-chloro-N,N-9-trimethyl-2-(6-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indole-4-carboxamide; ethyl 7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate; 4-[(4-azetidin-1-yl)piperidin-1-ylcarbonyl]-7-chloro-9-methyl-2-phenyl-9H-pyrimido-[4,5-b]indole; Alzheimer's or Parkinson's disease | SANOFI-AVENTIS (FR) | 2008-05-29 | — | — | US | disclosed |
| EP-1874777-A1 | H-PYRIMIDO[4,5-B]INDOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111648-A1 | H-PYRIMIDO[4,5-B]INDOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2006-10-26 | — | — | WO | disclosed |
| EP-0915879-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998001449-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196967-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | NNMT 1952/4885MKNK1 4569/4885MKNK2 4294/4885 |
| US-20090215741-A1 | 1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and Therapeutic Use | IDO1, IDO2, TPH1 | NNMT 455/4885MKNK1 3258/4885MKNK2 2463/4885 |
| US-20080125410-A1 | 7-chloro-N,N-9-trimethyl-2-(6-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indole-4-carboxamide; ethyl 7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate; 4-[(4-azetidin-1-yl)piperidin-1-ylcarbonyl]-7-chloro-9-methyl-2-phenyl-9H-pyrimido-[4,5-b]indole; Alzheimer's or Parkinson's disease | PARK7, SNCA, PSEN2 | NNMT 200/4885MKNK1 1466/4885MKNK2 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.